Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

dc.date.accessioned	2023-03-06T07:31:51Z
dc.date.available	2023-03-06T07:31:51Z
dc.date.issued	2022
dc.identifier.citation	J Cancer Res Ther. 2022 Dec;18(Supplement):S347-S353. doi: 10.4103/jcrt.jcrt_1104_21.
dc.identifier.uri	https://hdl.handle.net/20.500.12619/100024
dc.relation.isversionof	10.4103/jcrt.jcrt_1104_21
dc.relation.isversionof	10.4103/jcrt.jcrt_1104_21
dc.title	Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
dc.relation.journal	J Cancer Res Ther
dc.identifier.doi	10.4103/jcrt.jcrt_1104_21
dc.contributor.author	Erol C
dc.contributor.author	Erol C
dc.contributor.author	Nahit Sendur MA
dc.contributor.author	Bilgetekin I
dc.contributor.author	Garbioglu DB
dc.contributor.author	Hamdard J
dc.contributor.author	Akbas S
dc.contributor.author	Hizal M